title: Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk.
abstract: Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.
authors.affiliation: Department of General Internal Medicine, Head, Endocrinology, Diabetes and Metabolism, Asklepios Clinic St Georg, Hamburg, Germany d.mueller-wieland@asklepios.com.
authors.forename: Dirk
authors.initials: D
authors.lastname: Müller-Wieland
authors.affiliation: Assmann-Foundation for Prevention, Münster, Germany.
authors.forename: Gerd
authors.initials: G
authors.lastname: Assmann
authors.affiliation: Universitat de València and Director-General of Fundación INCLIVA, Valencia, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Carmena
authors.affiliation: Institut de recherches cliniques de Montréal (IRCM), Faculty of Medicine at the Université de Montréal, Canada.
authors.forename: Jean
authors.initials: J
authors.lastname: Davignon
authors.affiliation: Institute of Clinical Chemistry of the University Hospital of Zurich, Switzerland.
authors.forename: Arnold
authors.initials: A
authors.lastname: von Eckardstein
authors.affiliation: Department Public Health, Medical School University of Naples Federico II, Italy.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Farinaro
authors.affiliation: Hanseatic Heart Centre, Asklepios Clinic St Georg, Hamburg, Germany.
authors.forename: Heiner
authors.initials: H
authors.lastname: Greten
authors.affiliation: Department of Medicine and Health, Faculty of Health Sciences, University of Linköping and Stockholm Heart Centre, Sweden.
authors.forename: Anders G
authors.initials: AG
authors.lastname: Olsson
authors.affiliation: Institute for Laboratory Medicine, St Gallen, Switzerland.
authors.forename: Walter F
authors.initials: WF
authors.lastname: Riesen
authors.affiliation: Almazov Research Institute of Cardiology, Russian Federation Agency of Health and Social Development, Saint Petersburg, Russia.
authors.forename: Evgenyi
authors.initials: E
authors.lastname: Shlyakhto
mesh_terms: D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood*; D015897:Comorbidity; D032921:Consensus; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Hypercholesterolaemia; cardiovascular prevention